Treatment of Crohn's disease with anti-TNF alpha antibodies (infliximab): Results of a multicentric and retrospective study;Traitement de la maladie de Crohn par anticorps anti-TNF alpha (infliximab): Résultats d'une étude multicentrique et rétrospective

Gastroenterologie Clinique et Biologique

Volumn 26, Issue 11, 2002, Pages 973-979

  Doubremelle, Marie ^a   Bourreille, Arnaud ^a   Zerbib, Frank ^b   Heresbach, Denis ^c   Metman, Etienne Henry ^d   Beau, Philippe ^e   Gournay, Jérôme ^a   Galmiche, Jean Paul ^a  

^a HÔTEL DIEU   (France)

^b HÔPITAL SAINT ANDRÉ   (France)

^c PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^d SERVICE DE DERMATOLOGIE   (France)

^e Hepato Gastroenterologie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTICLE; CLINICAL TRIAL; CROHN DISEASE; DRUG EFFICACY; FEMALE; FOLLOW UP; FRANCE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RELAPSE; REMISSION; RETROSPECTIVE STUDY; UNIVERSITY HOSPITAL;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DATA INTERPRETATION, STATISTICAL; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; MALE; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 0036861920     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129-35.
2. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
3. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
4. D'haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology 1999;116:1029-34.
5. Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999;116:22-8.
6. Rutgeerts P, D'haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9.
7. Rutgeerts P, Schreiber S, Colombel JF, Rachmilewicz D, Malchow H, Mayer L, et al. Maintenance infliximab (Remicade) is safe, effective, and steroid-sparing in Crohn's disease (abstract). Gut 2001 49;suppl III:A3051.
8. Conférence de consensus « Helicobacter pylori ». Conclusions et recommandations révisées du groupe de travail. Gastroenterol Clin Biol 1999;23:C95-104.
9. Lamouliatte H, Talbi P, Cayla R, Zerbib F. Mégraud F. Randomised study comparing two seven days triple thérapies with lansoprazole and low dose of clarithromycin plus amoxicillin or tinidazole for H.pylori eradication (abstract). Gut 1996;39 (suppl 2):A35.
10. Lamouliatte H, Forestier S, Périé F. Lansoprazole 30mg or 60 mg with two antibiotics (amoxicillin-clarithomycin) for Helicobacter Pylori eradication (abstract). Gut 1998;43 (suppl 2):A80.
11. Farrell RJ, Shah SA, Lodhavia PJ, Alsahli M, Falchuk KR, Michetti P, et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 2000;95:3490-7.
12. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: First anniversary clinical experience. Am J Gastroenterol 2000;95:3469-77.
13. Arnott ID, McDonald D, Williams A, Ghosh S. Clinical use of Infliximab in Crohn's disease: The Edinburgh experience. Aliment Pharmacol Ther 2001;15:1639-46.
14. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: The first 100 patients. Am J Gastroenterol 2001;96:722-9.
15. Ouraghi A, Nieuviarts S, Mougenel JL, Allez M, Barthet M, Carbonnel F, et al. Traitement par anticorps anti-TNF alpha (infliximab, Remicade®) des lésions anopérinéales de la maladie de Crohn. Gastroenterol Clin Biol 2001;25:949-56.
16. Bernades P, Hecketsweiler P, Benozio M, Descos L, Geffroy Y, Hemet J, et al. Proposition de critères pour le diagnostic des maladies inflammatoires intestinales cryptogénétiques (Maladie de Crohn et rectocolite hémorragique). Gastroenterol Clin Biol 1978;2:1047-54.
17. Best WR, Becktel JM, Singleton JW, Kern F, Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-44.
18. Williams DR, Coller JA, Corman ML, Nugent FW, Veidenheimer MC. Anal complications in Crohn's disease. Dis Colon Rectum 1981;24:22-4.
19. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
20. Keane J, Gershon S. Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha- neutralizing agent. N Engl J Med 2001;345:1098-104.
21. Hanauer SB, Rutgeerts P, D'Haens G. Delayed hypersensibility to infliximab (remicade) re-infusion after a 2-4 year interval without treatment (abstract). Gastroenterology 1999;116:A731.